Back to Search Start Over

Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold.

Authors :
Li Z
Ishida R
Liu Y
Wang J
Li Y
Gao Y
Jiang J
Che J
Sheltzer JM
Robers MB
Zhang T
Westover KD
Nabet B
Gray NS
Source :
European journal of medicinal chemistry [Eur J Med Chem] 2022 Aug 05; Vol. 238, pp. 114433. Date of Electronic Publication: 2022 May 08.
Publication Year :
2022

Abstract

Cyclin-dependent kinases (CDK) are attractive targets for drug discovery due to their wide range of cellular functions. CDK11 is an understudied CDK with roles in transcription and splicing, cell cycle regulation, neuronal function, and apoptosis. In this study, we describe a medicinal chemistry campaign to identify a CDK11 inhibitor. Employing a promising but nonselective CDK11-targeting scaffold (JWD-047), extensive structure-guided medicinal chemistry modifications led to the identification of ZNL-05-044. A combination of biochemical evaluations and NanoBRET cellular assays for target engagement guided the SAR towards a 2,4-diaminothiazoles CDK11 probe with significantly improved kinome-wide selectivity over JWD-047. CDK11 inhibition with ZNL-05-044 leads to G2/M cell cycle arrest, consistent with prior work evaluating OTS964, and impacts CDK11-dependent mRNA splicing in cells. Together, ZNL-05-044 serves as a tool compound for further optimization and interrogation of the consequences of CDK11 inhibition.<br /> (Copyright © 2022. Published by Elsevier Masson SAS.)

Details

Language :
English
ISSN :
1768-3254
Volume :
238
Database :
MEDLINE
Journal :
European journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
35597007
Full Text :
https://doi.org/10.1016/j.ejmech.2022.114433